FOLH1 and prostate carcinoma: In prostate cancer, PSMA is overexpressed 100 to 1,000 times more than in normal cells, making it an interesting target for imaging and therapeutic tools and enabling this ‘image and treat’ strategy to become an important approach for patients with prostate cancer (7).